The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Robert A. Rosenheck

Yale Medical School

New Haven

USA

[email]@yale.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Yale Medical School, New Haven, USA. 2008 - 2009
  • Veterans Affairs New England Mental Illness Research, Education, and Clinical Center in West Haven, Connecticut, USA. 2001 - 2009
  • Department of Psychiatry, Yale Medical School, New Haven, CT 06516, USA. 2001 - 2008
  • Veterans Affairs Connecticut Healthcare System, West Haven 06516-2770, USA. 1998 - 2008
  • Yale Department of Psychiatry, New Haven, USA. 2007
  • Yale Medical School, Northeast Program Evaluation Center (182), VA Connecticut Health Care System, 950 Campbell Ave., USA. 1998 - 2007
  • Department of Veterans Affairs Northeast Program Evaluation Center, West Haven, CT 06516, USA. 1998 - 2006
  • University of North Carolina, Chapel Hill, USA. 2006
  • Northeast Program Evaluation Center, New England MIRECC, and Yale University School of Medicine, West Haven, USA. 2003
  • Yale Departments of Psychiatry and Epidemiology and Public Health, New Haven, Connecticut, USA. 2003
  • VA Connecticut Healthcare System, VA Connecticut-Massachusetts Mental Illness Research, Education and Clinical Center, West Haven 06516, USA. 1998 - 2000
  • Department of Veterans Affairs in West Haven, Connecticut, USA. 2000

References

  1. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Rosenheck, R.A., Davis, V.G., Davis, S.M., Stroup, S., McEvoy, J., Swartz, M., Lieberman, J. Schizophr. Res. (2009) [Pubmed]
  2. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Rosenheck, R.A., Davis, S., Covell, N., Essock, S., Swartz, M., Stroup, S., McEvoy, J., Lieberman, J. Schizophr. Res. (2009) [Pubmed]
  3. Developing a policy for second-generation antipsychotic drugs. Rosenheck, R.A., Sernyak, M.J. Health. Aff. (Millwood) (2009) [Pubmed]
  4. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. Rosenheck, R.A., Leslie, D.L., Doshi, J.A. Psychiatr. Serv (2008) [Pubmed]
  5. Rethinking antipsychotic formulary policy. Rosenheck, R.A., Leslie, D.L., Busch, S., Rofman, E.S., Sernyak, M. Schizophr. Bull (2008) [Pubmed]
  6. Pharmacotherapy of first-episode schizophrenia. Rosenheck, R.A. Lancet (2008) [Pubmed]
  7. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Rosenheck, R.A. Br. J. Psychiatry (2007) [Pubmed]
  8. Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Rosenheck, R., Swartz, M., McEvoy, J., Stroup, T.S., Davis, S., Keefe, R.S., Hsiao, J., Lieberman, J. Expert. Rev. Pharmacoecon. Outcomes. Res (2007) [Pubmed]
  9. Recent trends In VA treatment of post-traumatic stress disorder and other mental disorders. Rosenheck, R.A., Fontana, A.F. Health. Aff. (Millwood) (2007) [Pubmed]
  10. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Rosenheck, R.A., Leslie, D.L., Sindelar, J.L., Miller, E.A., Tariot, P.N., Dagerman, K.S., Davis, S.M., Lebowitz, B.D., Rabins, P., Hsiao, J.K., Lieberman, J.A., Schneider, L.S. Arch. Gen. Psychiatry (2007) [Pubmed]
  11. Implementation of supported employment for homeless veterans with psychiatric or addiction disorders: two-year outcomes. Rosenheck, R.A., Mares, A.S. Psychiatr. Serv (2007) [Pubmed]
  12. Barriers to employment for people with schizophrenia. Rosenheck, R., Leslie, D., Keefe, R., McEvoy, J., Swartz, M., Perkins, D., Stroup, S., Hsiao, J.K., Lieberman, J. Am. J. Psychiatry (2006) [Pubmed]
  13. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Rosenheck, R.A., Leslie, D.L., Sindelar, J., Miller, E.A., Lin, H., Stroup, T.S., McEvoy, J., Davis, S.M., Keefe, R.S., Swartz, M., Perkins, D.O., Hsiao, J.K., Lieberman, J. Am. J. Psychiatry (2006) [Pubmed]
  14. Introduction to the special section on CATIE baseline data: practical clinical trials in psychiatry: studies of schizophrenia from the CATIE network. Rosenheck, R.A., Swartz, M.S., Lieberman, J.A. Psychiatr. Serv (2006) [Pubmed]
  15. Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Rosenheck, R.A. Arch. Gen. Psychiatry (2006) [Pubmed]
  16. Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Rosenheck, R.A. Psychiatr. Serv (2005) [Pubmed]
  17. A longitudinal perspective on monitoring outcomes of an innovative program. Rosenheck, R.A., Seibyl, C.L. Psychiatr. Serv (2005) [Pubmed]
  18. The growth of psychopharmacology in the 1990s: evidence-based practice or irrational exuberance. Rosenheck, R. Int. J. Law. Psychiatry (2005) [Pubmed]
  19. Measuring outcome priorities and preferences in people with schizophrenia. Rosenheck, R., Stroup, S., Keefe, R.S., McEvoy, J., Swartz, M., Perkins, D., Hsiao, J., Shumway, M., Lieberman, J. Br. J. Psychiatry (2005) [Pubmed]
  20. Therapeutic limit setting and six-month outcomes in a Veterans Affairs assertive community treatment program. Rosenheck, R.A., Neale, M.S. Psychiatr. Serv (2004) [Pubmed]
  21. Back to the future: funding, integrating, and improving mental health services. Rosenheck, R.A. Psychiatr. Serv (2004) [Pubmed]
  22. Fiscal strain and access to opiate substitution therapy at Department of Veterans Affairs Medical Centers. Rosenheck, R., Leslie, D., Woody, G. Am. J. Addict (2003) [Pubmed]
  23. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Rosenheck, R., Doyle, J., Leslie, D., Fontana, A. Schizophr. Bull (2003) [Pubmed]
  24. Use of mental health services by veterans with PTSD after the terrorist attacks of September 11. Rosenheck, R., Fontana, A. Am. J. Psychiatry (2003) [Pubmed]
  25. Closing service system gaps for homeless clients with a dual diagnosis: integrated teams and interagency cooperation. Rosenheck, R.A., Resnick, S.G., Morrissey, J.P. J. Ment. Health. Policy. Econ (2003) [Pubmed]
  26. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Rosenheck, R., Perlick, D., Bingham, S., Liu-Mares, W., Collins, J., Warren, S., Leslie, D., Allan, E., Campbell, E.C., Caroff, S., Corwin, J., Davis, L., Douyon, R., Dunn, L., Evans, D., Frecska, E., Grabowski, J., Graeber, D., Herz, L., Kwon, K., Lawson, W., Mena, F., Sheikh, J., Smelson, D., Smith-Gamble, V. JAMA (2003) [Pubmed]
  27. Post-september 11 admission symptoms and treatment response among veterans with posttraumatic stress disorder. Rosenheck, R.A., Fontana, A. Psychiatr. Serv (2003) [Pubmed]
  28. Administrative prescription review procedures and use of atypical antipsychotic medications in the Department of Veterans Affairs. Rosenheck, R., Leslie, D. Ment. Health. Serv. Res (2003) [Pubmed]
  29. Service systems integration and outcomes for mentally ill homeless persons in the ACCESS program. Access to Community Care and Effective Services and Supports. Rosenheck, R.A., Lam, J., Morrissey, J.P., Calloway, M.O., Stolar, M., Randolph, F. Psychiatr. Serv (2002) [Pubmed]
  30. Impact of efforts to reduce inpatient costs on clinical effectiveness: treatment of posttraumatic stress disorder in the Department of Veterans Affairs. Rosenheck, R., Fontana, A. Med. Care (2001) [Pubmed]
  31. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Rosenheck, R., Leslie, D., Sernyak, M. Med. Care (2001) [Pubmed]
  32. Impact of VA bed closures on use of state psychiatric services. Rosenheck, R., Frisman, L., Essock, S. J. Behav. Health. Serv. Res (2001) [Pubmed]
  33. Buprenorphine for opiate addiction: potential economic impact. Rosenheck, R., Kosten, T. Drug. Alcohol. Depend (2001) [Pubmed]
  34. Time-limited assertive community treatment for homeless persons with severe mental illness. Rosenheck, R.A., Dennis, D. Arch. Gen. Psychiatry (2001) [Pubmed]
  35. Organizational process: a missing link between research and practice. Rosenheck, R.A. Psychiatr. Serv (2001) [Pubmed]
  36. The delivery of mental health services in the 21st century: bringing the community back in. Rosenheck, R. Community. Ment. Health. J (2000) [Pubmed]
  37. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Rosenheck, R., Chang, S., Choe, Y., Cramer, J., Xu, W., Thomas, J., Henderson, W., Charney, D. J. Clin. Psychiatry (2000) [Pubmed]
  38. Cost-effectiveness of services for mentally ill homeless people: the application of research to policy and practice. Rosenheck, R. Am. J. Psychiatry (2000) [Pubmed]
  39. Bed closures and incarceration rates among users of Veterans Affairs mental health services. Rosenheck, R.A., Banks, S., Pandiani, J., Hoff, R. Psychiatr. Serv (2000) [Pubmed]
  40. Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Rosenheck, R., Cramer, J., Jurgis, G., Perlick, D., Xu, W., Thomas, J., Henderson, W., Charney, D. J. Clin. Psychiatry (2000) [Pubmed]
  41. Outcomes after initial receipt of social security benefits among homeless veterans with mental illness. Rosenheck, R.A., Dausey, D.J., Frisman, L., Kasprow, W. Psychiatr. Serv (2000) [Pubmed]
  42. Improving access to disability benefits among homeless persons with mental illness: an agency-specific approach to services integration. Rosenheck, R., Frisman, L., Kasprow, W. Am. J. Public. Health (1999) [Pubmed]
  43. Principles for priority setting in mental health services and their implications for the least well off. Rosenheck, R.A. Psychiatr. Serv (1999) [Pubmed]
  44. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Rosenheck, R., Cramer, J., Allan, E., Erdos, J., Frisman, L.K., Xu, W., Thomas, J., Henderson, W., Charney, D. Arch. Gen. Psychiatry (1999) [Pubmed]
  45. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Rosenheck, R., Evans, D., Herz, L., Cramer, J., Xu, W., Thomas, J., Henderson, W., Charney, D. Schizophr. Bull (1999) [Pubmed]
  46. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Rosenheck, R., Dunn, L., Peszke, M., Cramer, J., Xu, W., Thomas, J., Charney, D. Am. J. Psychiatry (1999) [Pubmed]
  47. Cost-effectiveness of intensive psychiatric community care for high users of inpatient services. Rosenheck, R.A., Neale, M.S. Arch. Gen. Psychiatry (1998) [Pubmed]
  48. Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Rosenheck, R., Tekell, J., Peters, J., Cramer, J., Fontana, A., Xu, W., Thomas, J., Henderson, W., Charney, D. Arch. Gen. Psychiatry (1998) [Pubmed]
  49. Intensive community-focused treatment of veterans with dual diagnoses. Rosenheck, R., Harkness, L., Johnson, B., Sweeney, C., Buck, N., Deegan, D., Kosten, T. Am. J. Psychiatry (1998) [Pubmed]
  50. Obligation to the least well off in setting mental health service priorities: a consensus statement. Rosenheck, R., Armstrong, M., Callahan, D., Dea, R., Del Vecchio, P., Flynn, L., Fox, R.C., Goldman, H.H., Horvath, T., Munoz, R. Psychiatr. Serv (1998) [Pubmed]
  51. Service system integration, access to services, and housing outcomes in a program for homeless persons with severe mental illness. Rosenheck, R., Morrissey, J., Lam, J., Calloway, M., Johnsen, M., Goldman, H., Randolph, F., Blasinsky, M., Fontana, A., Calsyn, R., Teague, G. Am. J. Public. Health (1998) [Pubmed]
 
WikiGenes - Universities